https://journals.accscience.com/index.php/TD AccScience Publishing en-US Tumor Discovery 2810-9775 <p><strong><em>Copyright</em></strong></p> <p>The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.</p> <p>&nbsp;</p> <p><strong><em>License</em></strong></p> <p><em>Tumor Discovery</em> publishes accepted manuscripts under&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener"><strong>Creative Commons Attribution 4.0 International License (CC BY 4.0)</strong></a>. Authors who submit their papers for publication by&nbsp;<em>Tumor Discovery</em> agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use, as long as the author and original source is properly cited, anyone may copy, redistribute, reuse and transform the content.</p> <p>For more information, refer to the journal’s&nbsp;<strong>Copyright and License</strong>&nbsp;section on the <strong>About the Journal </strong>section.</p> https://journals.accscience.com/index.php/TD/article/view/342 <p>There is great interest in accelerating late-stage therapy development by efficiently performing a trial design with multiple therapies or multiple subpopulations simultaneously under a single protocol. The master protocols are termed to describe the design of such trials, with a variety of terms such as umbrella, basket, or platform describing specific designs, which are, in contrast to the traditional trial designs, full of complexity. What should we consider in designing a trial ensuring the safety of human subjects and demonstrating the efficacy of new therapy? This paper overviews the master protocol framework, comprehensively unifies the definitions and illustrates essential design elements of representative example trials conducted in drugs and medical devices. Besides, to understand the master protocols deeply, it is also a need to summarize the commonly-used types of master protocols in various disease and treatment fields, along with the reasons for these phenomena by analyzing the characteristics of the diseases, the mechanism of therapeutic products, and the principles of various types of master protocols. Finally, we also propose practical considerations, including the design, ethical, statistics, and funding considerations that arise from implementing complex master protocols to help practitioners better design and identify potential valuable therapies.</p> Jiali Song Zhiwei Rong Xinwen Zhong Yuhong Lu Jike Huang Yipei Yu Zhilin Liu Xuyuan Quan Nana Chen Kang Li Fengyu Sun Yan Hou Copyright (c) 2023 Author(s) https://creativecommons.org/licenses/by/4.0/ 2023-04-28 2023-04-28 2 2 342 342 10.36922/td.342 https://journals.accscience.com/index.php/TD/article/view/356 <p>Here, we report the clinical case of a 44-year-old lady, affected by synovial sarcoma (SS) of the mediastinum which was treated in 2014, and relapsed in the upper abdomen in 2020. SS is a relatively radioresistant disease, radiotherapy (RT) is routinely reserved for the neoadjuvant/adjuvant or palliative context. In our scenario, stereotactic RT consisting in 45Gy in 6 fractions was proposed to manage the upper abdominal relapse. Exploiting simultaneous integrated protection, a deliberated reduction in the dose prescription in area of planning target volume overlapped with stomach was achieved, obtaining reasonable dosimetric goals. Acute toxicity in the patient was acceptable, and she did not experience late toxicity and was still free from disease, as noted in last follow-up, 15 months after treatment.</p> Marco Lorenzo Bonù Eneida Mataj Jacopo Balduzzi Maria Teresa Cefaratti Gloria Pedersoli Gianluca Cossali Luca Triggiani Davide Tomasini Michela Buglione Stefano Maria Magrini Copyright (c) 2023 Author(s) https://creativecommons.org/licenses/by/4.0 2023-05-10 2023-05-10 2 2 356 356 10.36922/td.356